<DOC>
	<DOC>NCT00240305</DOC>
	<brief_summary>The purpose of this study is to investigate the dose-related effect of treatment with rosuvastatin on production and fractional catabolism of apolipoprotein A-I (apoA-I) and apolipoprotein A-II (apoA-II), and on the plasma apoA-I, apoA-II and high-density lipoprotein cholesterol (HDL-C) concentration.</brief_summary>
	<brief_title>A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Signed informed consent male aged 30 to 70 years of age LDLC &lt;6 mmol/L HDLC ≤1.2 mmol/L at least 2 of the following: insulin resistance (fasting glucose &gt;6 mmol/L or insulin &gt;10 mU/L or HOMA score &gt;2.5) central obesity (waist circumference &gt;=94 cm). plasma triglycerides &gt;=1.7 and &lt;4.5 mmol/L. blood pressure &gt;=130/ &gt;=85 mm Hg or on drug treatment for hypertension LDL cholesterol &gt;=6 mmol/L preexisting or history of cardiovascular disease, diabetes, renal dysfunction, anaemia, history of significant dyspepsia or gastrointestinal disease apolipoprotein genotype E2/E2</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>Dyslipidaemia</keyword>
</DOC>